Financhill
Buy
57

BVS Quote, Financials, Valuation and Earnings

Last price:
$10.47
Seasonality move :
-12.86%
Day range:
$10.27 - $10.80
52-week range:
$3.90 - $14.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.23x
P/B ratio:
4.69x
Volume:
538.3K
Avg. volume:
333K
1-year change:
104.8%
Market cap:
$697.5M
Revenue:
$512.3M
EPS (TTM):
-$0.60

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BVS
Bioventus
$133.2M $0.02 6.95% -97.08% $15.00
BSX
Boston Scientific
$4B $0.59 18.39% 92.99% $99.00
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% --
PODD
Insulet
$519.3M $0.76 14.22% -29.37% $285.63
VTAK
Catheter Precision
$290K -$2.60 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$29.3M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BVS
Bioventus
$10.67 $15.00 $697.5M -- $0.00 0% 1.23x
BSX
Boston Scientific
$88.95 $99.00 $131.1B 73.51x $0.00 0% 8.29x
CATX
Perspective Therapeutics
$2.85 -- $192.6M -- $0.00 0% 15.39x
PODD
Insulet
$266.55 $285.63 $18.7B 45.64x $0.00 0% 10.27x
VTAK
Catheter Precision
$0.33 -- $2.6M 0.38x $0.00 0% 0.88x
XTNT
Xtant Medical Holdings
$0.36 -- $50M -- $0.00 0% 0.42x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BVS
Bioventus
72.06% 3.407 47.02% 0.78x
BSX
Boston Scientific
34.45% 0.299 8.79% 0.85x
CATX
Perspective Therapeutics
-- -5.312 -- --
PODD
Insulet
55.57% 0.856 8.57% 2.53x
VTAK
Catheter Precision
12% -11.532 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 1.226 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BVS
Bioventus
$93.6M $6.6M -6.61% -18.97% 3.38% $10.3M
BSX
Boston Scientific
$2.9B $718M 5.95% 8.91% 17.77% $698M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
PODD
Insulet
$377.1M $88.1M 18.66% 49.55% 17.5% $69.4M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Bioventus vs. Competitors

  • Which has Higher Returns BVS or BSX?

    Boston Scientific has a net margin of -3.47% compared to Bioventus's net margin of 11.12%. Bioventus's return on equity of -18.97% beat Boston Scientific's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    BVS
    Bioventus
    67.32% -$0.07 $570.4M
    BSX
    Boston Scientific
    68.83% $0.32 $31.8B
  • What do Analysts Say About BVS or BSX?

    Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.58%. On the other hand Boston Scientific has an analysts' consensus of $99.00 which suggests that it could grow by 11.3%. Given that Bioventus has higher upside potential than Boston Scientific, analysts believe Bioventus is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BVS
    Bioventus
    2 1 0
    BSX
    Boston Scientific
    20 5 0
  • Is BVS or BSX More Risky?

    Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

  • Which is a Better Dividend Stock BVS or BSX?

    Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BVS or BSX?

    Bioventus quarterly revenues are $139M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Bioventus's net income of -$4.8M is lower than Boston Scientific's net income of $468M. Notably, Bioventus's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 73.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 8.29x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BVS
    Bioventus
    1.23x -- $139M -$4.8M
    BSX
    Boston Scientific
    8.29x 73.51x $4.2B $468M
  • Which has Higher Returns BVS or CATX?

    Perspective Therapeutics has a net margin of -3.47% compared to Bioventus's net margin of --. Bioventus's return on equity of -18.97% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BVS
    Bioventus
    67.32% -$0.07 $570.4M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About BVS or CATX?

    Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.58%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Bioventus, analysts believe Perspective Therapeutics is more attractive than Bioventus.

    Company Buy Ratings Hold Ratings Sell Ratings
    BVS
    Bioventus
    2 1 0
    CATX
    Perspective Therapeutics
    0 0 0
  • Is BVS or CATX More Risky?

    Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock BVS or CATX?

    Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BVS or CATX?

    Bioventus quarterly revenues are $139M, which are larger than Perspective Therapeutics quarterly revenues of --. Bioventus's net income of -$4.8M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Bioventus's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BVS
    Bioventus
    1.23x -- $139M -$4.8M
    CATX
    Perspective Therapeutics
    15.39x -- -- -$15.1M
  • Which has Higher Returns BVS or PODD?

    Insulet has a net margin of -3.47% compared to Bioventus's net margin of 14.25%. Bioventus's return on equity of -18.97% beat Insulet's return on equity of 49.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    BVS
    Bioventus
    67.32% -$0.07 $570.4M
    PODD
    Insulet
    69.33% $1.08 $2.5B
  • What do Analysts Say About BVS or PODD?

    Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.58%. On the other hand Insulet has an analysts' consensus of $285.63 which suggests that it could grow by 7.16%. Given that Bioventus has higher upside potential than Insulet, analysts believe Bioventus is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    BVS
    Bioventus
    2 1 0
    PODD
    Insulet
    14 4 0
  • Is BVS or PODD More Risky?

    Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.859%.

  • Which is a Better Dividend Stock BVS or PODD?

    Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BVS or PODD?

    Bioventus quarterly revenues are $139M, which are smaller than Insulet quarterly revenues of $543.9M. Bioventus's net income of -$4.8M is lower than Insulet's net income of $77.5M. Notably, Bioventus's price-to-earnings ratio is -- while Insulet's PE ratio is 45.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 10.27x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BVS
    Bioventus
    1.23x -- $139M -$4.8M
    PODD
    Insulet
    10.27x 45.64x $543.9M $77.5M
  • Which has Higher Returns BVS or VTAK?

    Catheter Precision has a net margin of -3.47% compared to Bioventus's net margin of -4291.67%. Bioventus's return on equity of -18.97% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    BVS
    Bioventus
    67.32% -$0.07 $570.4M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About BVS or VTAK?

    Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.58%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than Bioventus, analysts believe Catheter Precision is more attractive than Bioventus.

    Company Buy Ratings Hold Ratings Sell Ratings
    BVS
    Bioventus
    2 1 0
    VTAK
    Catheter Precision
    0 0 0
  • Is BVS or VTAK More Risky?

    Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

  • Which is a Better Dividend Stock BVS or VTAK?

    Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BVS or VTAK?

    Bioventus quarterly revenues are $139M, which are larger than Catheter Precision quarterly revenues of $96K. Bioventus's net income of -$4.8M is lower than Catheter Precision's net income of -$4.1M. Notably, Bioventus's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BVS
    Bioventus
    1.23x -- $139M -$4.8M
    VTAK
    Catheter Precision
    0.88x 0.38x $96K -$4.1M
  • Which has Higher Returns BVS or XTNT?

    Xtant Medical Holdings has a net margin of -3.47% compared to Bioventus's net margin of -17.98%. Bioventus's return on equity of -18.97% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    BVS
    Bioventus
    67.32% -$0.07 $570.4M
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About BVS or XTNT?

    Bioventus has a consensus price target of $15.00, signalling upside risk potential of 40.58%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than Bioventus, analysts believe Xtant Medical Holdings is more attractive than Bioventus.

    Company Buy Ratings Hold Ratings Sell Ratings
    BVS
    Bioventus
    2 1 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is BVS or XTNT More Risky?

    Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

  • Which is a Better Dividend Stock BVS or XTNT?

    Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BVS or XTNT?

    Bioventus quarterly revenues are $139M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Bioventus's net income of -$4.8M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Bioventus's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.23x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BVS
    Bioventus
    1.23x -- $139M -$4.8M
    XTNT
    Xtant Medical Holdings
    0.42x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 1.41% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 8.63% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.77% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock